Tirzepatide, also known as LY3298176, is a synthetic dual receptor agonist peptide, capable of activating both GLP?1 receptor and GIP receptor simultaneously, which makes it a highly researched molecule in metabolic related research fields. The GLP?1 pathway promotes insulin secretion in a glucose-dependent manner, suppresses glucagon release, delays gastric emptying and enhances satiety signals. The synergistic activation of GIP receptor further modulates energy metabolism and adipose tissue signaling, generating combined effects through dual pathways. In animal model studies, this compound is widely applied in research projects covering obesity, insulin resistance, type 2 diabetes mellitus, lipid metabolism disorder and other related topics.

Manufactured by advanced solid-phase peptide synthesis technology, the product is purified by multi-step reversed-phase chromatography to remove truncated peptides with missing amino acids, oxidative impurities and residual organic solvents. Each batch comes with complete COA certification documents, including HPLC purity detection, MS molecular weight verification, moisture test, residual solvent test, endotoxin and microbial limit inspection to guarantee stable consistency between batches. Lyophilized formulation greatly reduces the risk of peptide hydrolysis and degradation, improving stability during cross-border transportation. It fits multiple research scenarios such as in-vitro cellular receptor binding assay, protein signal pathway exploration, in-vivo animal pharmacodynamic evaluation, peptide stability testing and so forth.